Urea derivatives and uses thereof
The present invention provides novel compounds of any one of Formulae (I)-(III), and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of Formula (I)-(III) and pharmaceutical compositions thereof that are mucus penetrating. The invention also provides methods and kits for using the inventive compounds, and pharmaceutical compositions thereof, for treating and/or preventing diseases associated with abnormal or pathological angiogenesis and/or aberrant signaling of a growth factor (e.g., vascular endothelial growth factor (VEGF)), such as proliferative diseases (e.g., cancers, benign neoplasms, inflammatory diseases, autoimmune diseases) and ocular diseases (e.g., macular degeneration, glaucoma, diabetic retinopathy, retinoblastoma, edema, uveitis, dry eye, blepharitis, and post-surgical inflammation) in a subject in need thereof.
1. A compound of the formula:
or a pharmaceutically acceptable salt thereof;
wherein
each instance of R M is independently hydrogen, halogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —OR M1 , —N(R M1 ) 2 , —SR M1 , —CN, —SCN, —C(═NR M1 )R M1 , —C(═NR M1 )OR M1 , —C(═NR M1 )N(R M1 ) 2 , —C(═O) R M1 , —C(═O)OR M1 , —C(═O)N(R M1 ) 2 , —NO 2 , —NR M1 C(═O)R M1 , —NR M1 C(═O)OR M1 , —NR M1 C(═O) N(R M1 ) 2 , —OC(═O)R M1 , —OC(═O)OR M1 , or —OC(═O) N(R M1 ) 2 , or two instances of R M are joined to form substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
each instance of R M1 is independently hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, a nitrogen protecting group when attached to a nitrogen atom, an oxygen protecting group when attached to an oxygen atom, or a sulfur protecting group when attached to a sulfur atom, or two instances of R M1 are joined to form substituted or unsubstituted heterocyclyl;
R L is substituted or unsubstituted alkyl, a nitrogen protecting group, or of the formula:
Ring L is substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
each instance of R L1 is independently hydrogen, halogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —OR L1a , —N(R L1a ) 2 , —SR L1a , —CN, —SCN, —C(═NR L1a )R L1a , —C(═NR L1a )OR L1a , —C(═NR L1a )N(R L1a ) 2 , —C(═O)R L1a , —C(═O)OR L1a , —C(═O) N(R L1a ) 2 , —NO 2 , —NR L1a C(═O)R L1a , —NR L1a C(═O)OR L1a , NR L1a C(═O)N(R L1a ) 2 , —OC(═O) R L1a , —OC(═O)OR L1a , —OC(═O)N(R L1a ) 2 , or a nitrogen protecting group when attached to a nitrogen atom, or two instances of R L1 are joined to form substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
each instance of R L1a is independently hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, a nitrogen protecting group when attached to a nitrogen atom, an oxygen protecting group when attached to an oxygen atom, or a sulfur protecting group when attached to a sulfur atom, or two instances of R L1a are joined to form substituted or unsubstituted heterocyclyl;
R N is hydrogen, substituted or unsubstituted C 1-6 alkyl, or a nitrogen protecting group;
R P is hydrogen, substituted or unsubstituted C 1-6 alkyl, or a nitrogen protecting group;
m is 0, 1, 2, 3, or 4; and
l is 0, 1, 2, 3, 4, or 5.
2. The compound of claim 1 , wherein the compound is of the formula:
or a pharmaceutically acceptable salt thereof.
3. The compound of claim 1 , wherein the compound is of the formula:
or a pharmaceutically acceptable salt thereof.
4. The compound of claim 1 , wherein the compound is of the formula:
or a pharmaceutically acceptable salt thereof.
5. The compound of claim 1 , wherein the compound is of the formula:
or a pharmaceutically acceptable salt thereof.
6. The compound of claim 1 , wherein the compound is of the formula:
or a pharmaceutically acceptable salt thereof.
7. The compound of claim 1 , wherein the compound is of the formula:
or a pharmaceutically acceptable salt thereof.
8. The compound of claim 1 , wherein l is 2.
9. The compound of claim 1 , wherein R L1 is halogen or C 1-6 alkyl.
10. The compound of claim 1 , wherein R L is
11. The compound of claim 1 , wherein R N is hydrogen.
12. The compound of claim 1 , wherein m is 0.
13. The compound of claim 1 , wherein m is hydrogen.
14. The compound of claim 1 , wherein m is 0.
15. The compound of claim 1 , wherein R M is hydrogen, halogen, or C 1-6 alkyl.
16. A composition, comprising the compound of claim 1 .
17. A pharmaceutical composition, comprising the compound of claim 1 and a pharmaceutically acceptable excipient.
18. The pharmaceutical composition of claim 17 , suitable for topical administration to an eye of a subject.
19. A method of inhibiting growth factor signaling in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound of claim 1 .
20. A method of inhibiting growth factor signaling in a cell, comprising contacting the cell with an effective amount of the compound of claim 1 .